Streetbeat News

Regulatory

PDSB

PDS Biotechnology Corporation (NASDAQ:PDSB) has announced interim safety and immune response data from a Phase 1/2 clinical trial for PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with docetaxel, to treat metastatic prostate cancer. The data will be presented at the 11th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2023) in Athens, Greece.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:03 pm

ALUR

Allurion Technologies, Inc. (NYSE:ALUR) has completed patient enrollment in its AUDACITY trial, which is designed to support FDA approval of the Allurion Balloon, a novel weight loss device. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. The Allurion Balloon is a swallowable, procedure-less gastric balloon for weight loss.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:03 pm

LCTX

Lineage Cell Therapeutics, Inc. (LCTX) has been granted a U.S. patent for its proprietary manufacturing and differentiation process for retinal pigmented epithelial cells. The patent, which is exclusively licensed to Lineage, is expected to expire on July 28, 2036. The patented process is used in the development of RG6501 (OpRegen®), a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The program is being developed in collaboration with Roche and Genentech.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:01 pm

EIS

SPY

USO

ZM

The Israel Education Ministry has announced that all schools will shift to remote learning starting Sunday, according to a statement cited by Reuters.

Portfolio Pulse from Charles Gross

October 11, 2023 | 11:53 am

EIS

SPY

USO

US Treasury Secretary Janet Yellen has warned Iran that no options are 'off the table' when it comes to sanctions. This could potentially impact the global oil market and subsequently, the performance of ETFs like EIS, SPY, and USO.

Portfolio Pulse from Charles Gross

October 11, 2023 | 11:50 am

PXD

XOM

Exxon's CEO, in an interview with CNBC, stated that they do not anticipate any regulatory issues with the Pioneer deal.

Portfolio Pulse from Charles Gross

October 11, 2023 | 11:39 am

VVOS

Vivos Therapeutics has announced that its flagship daytime-nighttime appliance will be tested in a clinical trial at Stanford Medicine. The protocol for the trial has been finalized and participant enrollment will begin in early 2024.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:38 am

PHIO

Phio Pharmaceuticals has announced the presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference. The data shows that melanoma cells treated with PH-894 become more recognizable to immune cells, increasing their potential for elimination. Additionally, PH-894 has demonstrated effectiveness as an antitumor cytotoxic agent.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:36 am

ZVSA

ZyVersa Therapeutics has announced a peer-reviewed publication in Nature Reviews Nephrology that substantiates the rationale for VAR 200's role in mediating the transport of cholesterol and lipids out of kidney cells to attenuate the progression of kidney disease.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:10 am

SKX

Skechers has secured a preliminary injunction against Dockers by Gerli across the European Union for infringing on Skechers' design patents for hands-free slip-ins.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:05 am